SCHEMBL145497

SCHEMBL145497

CS(=O)(=O)NCCCNc1nonc1/C(=N\O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 20/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145498 1.00 IDO1 (0.51) IDO1
SCHEMBL19465703 1.00 IDO1 (0.51) IDO1
SCHEMBL146607 0.94 IDO1 (0.58) IDO1
SCHEMBL19465774 0.94 IDO1 (0.58) IDO1
SCHEMBL146606 0.94 IDO1 (0.58) IDO1
SCHEMBL1838743 0.93 IDO1 (0.49) IDO1
SCHEMBL20198874 0.93 IDO1 (0.50) IDO1
SCHEMBL1838742 0.93 IDO1 (0.49) IDO1
SCHEMBL146948 0.91 IDO1 (0.62) IDO1
SCHEMBL146949 0.91 IDO1 (0.62) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10653677-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE HOLDINGS CORPORATION (US) 2020-05-19 US claimed
US-20190298700-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase INCYTE CORPORATION 2019-10-03 US claimed
EP-2824100-B1 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE HOLDINGS CORP (US) 2018-02-21 EP claimed
EP-2315756-B9 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORP (US) 2015-07-22 EP claimed
US-8993605-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-03-31 US claimed
EP-2824100-A1 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Incyte Corporation (US) 2015-01-14 EP claimed
US-20140315962-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase INCYTE CORPORATION (US) 2014-10-23 US claimed
EP-2315756-B1 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORP (US) 2014-09-03 EP claimed
US-8822511-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2014-09-02 US claimed
US-8796319-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2014-08-05 US claimed
US-20140023663-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase INCYTE CORPORATION (US) 2014-01-23 US claimed
US-20120058079-A1 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase INCYTE CORPORATION, A DELAWARE CORPORATION 2012-03-08 US claimed
US-8088803-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2012-01-03 US claimed
US-20100015178-A1 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION 2010-01-21 US claimed
US-20240173303-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase INCYTE HOLDINGS CORPORATION 2024-05-30 US disclosed
EP-2911669-B1 SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER UNIV CHICAGO (US) 2024-04-10 EP disclosed
US-20220331296-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase INCYTE CORPORATION 2022-10-20 US disclosed
US-20120058079-A1 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase INCYTE CORPORATION, A DELAWARE CORPORATION 2012-03-08 US disclosed
US-8088803-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2012-01-03 US disclosed
US-20100015178-A1 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315962-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase IDO1, IDO2, INMT IDO1 1/4885
US-20240173303-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase IDO1, IDO2, INMT IDO1 1/4885
US-10653677-B2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase IDO1, IDO2, INMT IDO1 1/4885
US-20190298700-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase IDO1, IDO2, INMT IDO1 1/4885
US-20140023663-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase IDO1, IDO2, INMT IDO1 1/4885
US-20100015178-A1 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT IDO1 1/4885
US-20220331296-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase IDO1, IDO2, INMT IDO1 1/4885
US-20120058079-A1 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase IDO1, IDO2, INMT IDO1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.